Content
February 2004, Volume 5, Issue 1
- 70-80 Economic burden of head and neck cancer
by Jennifer Lee & Marco Turini & Marc Botteman & Jennifer Stephens & Chris Pashos - 81-86 Chained time trade-off and standard gamble methods
by Paul McNamee & Sharon Glendinning & Jonathan Shenfine & Nick Steen & S. Griffin & John Bond
October 2004, Volume 5, Issue 1
- 4-4 A review of European studies on the economic burden of brain diseases
by Bengt Jönsson & Jes Olesen - 5-12 Economic evidence in addiction: a review
by Patrik Andlin-Sobocki - 12-20 Economic evidence in affective disorders: a review
by Mickael Löthgren - 20-25 Economic evidence in anxiety disorders: a review
by Mickael Löthgren - 25-30 Economic evidence in brain tumour: a review
by Mattias Ekman - 30-35 Economic evidence in dementia: a review
by Linus Jönsson - 36-42 Economic evidence in epilepsy: a review
by Mattias Ekman & Lars Forsgren - 43-54 Economic evidence in migraine and other headaches: a review
by Jenny Berg - 54-62 Economic evidence in multiple sclerosis: a review
by Gisela Kobelt - 63-66 Economic evidence in parkinson’s disease: a review
by Peter Lindgren - 67-74 Economic evidence in psychotic disorders: a review
by Mickael Löthgren - 74-83 Economic evidence in stroke: a review
by Mattias Ekman - 84-91 Economic evidence in trauma: a review
by Jenny Berg
December 2003, Volume 4, Issue 4
- 248-253 Economic burden of obesity and its complications in Germany
by Beate Sander & Rito Bergemann - 254-262 Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden
by Jonas Lundkvist & David Bergqvist & Bengt Jönsson - 263-270 Should one use smokeless tobacco in smoking cessation programs?
by Mikael Bask & Maria Melkersson - 271-278 A Markov model of treatment of newly diagnosed epilepsy in the UK
by E. Remák & J. Hutton & M. Price & K. Peeters & I. Adriaenssen - 279-285 Financial incentives and the supply of laboratory tests
by Fredrik Carlsen & Jostein Grytten & Irene Skau - 286-291 Health care reform in six Central European countries
by Mark Nuijten & Agota Szende & Jozsef Kosa & Zsolt Mogyorosy & Boris Kramberger & Karel Nemecek & Dominik Tomek & Stjepan Oreskovic & Monika Laskowska - 292-294 An exponential representation of health state utility
by Michael Happich & Axel Muehlbacher - 295-295 Testing assumptions of quality-adjusted life-year calculations
by Ariel Béresniak - 296-303 Project of Polish guidelines for conducting pharmacoeconomic evaluations in comparison to international health economic guidelines
by Ewa Orlewska & Piotr Mierzejewski - 304-312 Modeling risk-adjusted capitation rates for Umbria, Italy
by Elaine Yuen & Daniel Louis & Paolo Loreto & Joseph Gonnella - 313-318 The lag between effectiveness and cost-effectiveness evidence of new drugs
by Boyka Stoykova & Michael Drummond & Marco Barbieri & Jos Kleijnen - 319-326 Measles dynamics and vaccination diffusion
by Laurent Coudeville - 327-333 An overview of the Greek pharmaceutical market
by V. Kontozamanis & E. Mantzouneas & C. Stoforos
September 2003, Volume 4, Issue 3
- 143-150 When should decision-analytic modeling be used in the economic evaluation of health care?
by Uwe Siebert - 151-157 Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998–2001
by Josep Darbà - 158-175 A fuzzy logic approach toward solving the analytic enigma of health system financing
by Dov Chernichovsky & Arkady Bolotin & David Leeuw - 176-183 Scale of reference bias and the evolution of health
by Wim Groot - 184-194 Is therapeutic innovation responsible for the increase in drug expenditure?
by Philippe Cavalié - 195-202 Time to disable DALYs?
by Carl Lyttkens - 203-208 Costs and effectiveness of a syringe distribution and needle exchange program for HIV prevention in a regional setting
by Juan Cabasés & Eduardo Sánchez - 209-215 Economic evaluation of human papillomavirus screening in Germany
by T. Mittendorf & K. Petry & T. Iftner & W. Greiner & J. Schulenburg - 216-221 Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK
by Mike Aristides & Michael Lees & Nick Botwood & Jan McKendrick & Deborah Stephenson & Nikos Maniadakis - 222-231 A single European currency for EQ-5D health states
by Wolfgang Greiner & Tom Weijnen & Martin Nieuwenhuizen & Siem Oppe & Xavier Badia & Jan Busschbach & Martin Buxton & Paul Dolan & Paul Kind & Paul Krabbe & Arto Ohinmaa & David Parkin & Montserat Roset & Harri Sintonen & Aki Tsuchiya & Frank Charro - 232-238 The efficiency of treatment strategies of general practitioners
by Matthias Staat - 239-240 Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials"
by Jon Karnon & A. Brennan & J. Chilcott
September 2002, Volume 3, Issue 3
- 145-148 Measuring health system performance
by P.C. Smith - 149-155 Budget impact model for determining the costs of introducing inhaled salmeterol/fluticasone propionate combination for the management of persistent asthma in France
by B. Detournay & C. Pribil & C. Jourdanne & M. Price - 156-165 Disease progression in amyotrophic lateral sclerosis
by M. Tavakoli - 166-172 Costs of toxicity during chemotherapy with CHOP, COP/CVP, and fludarabine
by M. Herold & K. Hieke - 173-179 A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia
by K. Hansen & C. François & M. Toumi & C. Lançon - 180-187 Modelling the costs and effects of leflunomide in rheumatoid arthritis
by G. Kobelt & P. Lindgren & A. Young - 188-195 Medical savings accounts: a core feature of Singapore's health care system
by W. von Eiff & T. Massoro & Y. O. Voo & R. Ziegenbein - 196-206 Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards
by Ágota Szende & Z. Mogyorósy & N. Muszbek & J. Nagy & G. Pallos & C Dözsa - 207-214 Restructuring of the healthcare system and the diffusion of telemedicine
by M. Kerleau & N. Pelletier-Fleury - 215-220 Pricing and reimbursement of pharmaceuticals in Norway
by A. Hågå & J. M. Sverre
June 2002, Volume 3, Issue 2
- 73-76 Genetic testing and the health care system
by Oliver Schöffski - 77-82 Burden of illness imposed by severe sepsis in Germany
by A. Schmid & H. Burchardi & J. Clouth & H. Schneider - 83-93 Risk-adjusted capitation funding models for chronic disease in Australia: alternatives to casemix funding
by K. M. Antioch & M.K. Walsh - 94-102 The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom
by J. Bonastre & C. Le Pen & P. Anderson & A. Ganz & P. Berto & G. Berdeaux - 103-110 Reputation, public information, and physician adoption of an innovation
by J. G. Smythe - 111-119 Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine
by Lukas Radbruch & K. Lehmann & H.-H. Gockel & D. Neighbors & G. Nuyts - 120-124 Association of time preference for health with age and disease severity
by K. Stavem & I. S. Kristiansen & J. A. Olsen - 124-124 Erratum to: Does health technology assessment benefit health services and politics?
by H. Sigmund & F.B. Kristensen - 125-130 Is EQ-5D a valid measure of HRQoL in patients with movement disorders?
by S. Ghislandi & G. Apolone & L. Garattini & I. Ghislandi - 131-136 Developing a scoring system to quality assess economic evaluations
by J. G. Gonzalez-Perez - 137-138 Time for a change in drug licensing requirements?
by Michael F. Drummond - 138-138 Commentary
by J.-Matthias Graf Schulenburg - 139-139 Commentary
by Bengt Jönsson - 140-141 Time for a change in drug pricing : Going downstream
by Gérard Pouvourville - 141-142 Drug licensing requirements are changing!
by F. Lekkerkerker & F. Rutten - 142-142 A final comment
by Michael F. Drummond
March 2002, Volume 3, Issue 1
- 3-9 Costing hospital activity: the experience with healthcare resource groups in England
by A. Street & D. Dawson - 10-16 Comparing the results of applying different methods of eliciting time preferences for health
by Dorte Gyrd-Hansen - 17-25 Devolved budgetary responsibility in primary care
by P. Wilton & R. D. Smith - 26-39 Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction
by K. M. Antioch & G. Jennings & M. Botti & R. Chapman & V. Wulfsohn - 40-46 Priorities and Prospect Theory
by M. Happich & B. Mazurek - 47-53 Adapting portfolio theory for the evaluation of multiple investments in health with a multiplicative extension for treatment synergies
by J. F. P. Bridges & M. Stewart & M. T. King & K. van Gool - 54-58 Does health technology assessment benefit health services and politics?
by H. Sigmund & F. B. Kristensen - 59-65 Overview of economic evaluation of positron-emission tomography
by A. Müller & D. Stratmann-Schöne & T. Klose & R. Leidl - 66-70 Pricing and reimbursement of drugs in Sweden
by J. Lundkvist - 71-71 Report on the 4 th ISPOR European Annual Meeting in November 2001 in Cannes, France
by Wolfgang Greiner